Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

Abstract

PARP inhibitors have been proposed as a potential targeted therapy for patients with triple-negative (ER-, PR-, HER2-negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial. To better understand the mechanisms that determine the response to PARP inhibitors, we investigated whether enzymes involved in metabolism of the PARP substrate, β-NAD(+) , might alter the response to a clinical PARP inhibitor. Using an olaparib sensitization screen in a triple-negative (TN) breast cancer model, we identified nicotinamide phosphoribosyltransferase (NAMPT) as a non-redundant modifier of olaparib response. NAMPT is a rate-limiting enzyme involved in the generation of the PARP substrate β-NAD(+) and the suppression of β-NAD(+) levels by NAMPT inhibition most likely explains these observations. Importantly, the combination of a NAMPT small molecule inhibitor, FK866, with olaparib inhibited TN breast tumour growth in vivo to a greater extent than either single agent alone suggesting that assessing NAMPT/PARP inhibitor combinations for the treatment of TN breast cancer may be warranted.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 22

1. 1.

   Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. Gamma H2AX and cancer. Nat Rev Cancer. 2008;8:957-967.

   Not in our library10.1038/nrc2523

2. 2.
   Analysis of cell-based RNAi screens · 2006

   No notice
3. 3.
   Ubiquitin Ligase RNF146 Regulates Tankyrase and Axin to Promote Wnt Signaling · 2011

   No notice
4. 4.

   Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer. 2010;103:1588-1596.

   Not in our library10.1038/sj.bjc.6605946

5. 5.

   Drevs J, Loser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res. 2003;23:4853-4858.

   Not in our library

6. 6.

   Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods. 2006;3:777-779.

   Not in our library10.1038/nmeth1006-777

7. 7.

   Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111-1115.

   Not in our library10.1038/nature06548

8. 8.

   Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.

   Not in our library10.1038/nature03445

9. 9.

   Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948.

   Not in our library10.1056/nejmra1001389

10. 10.

    Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20:130-138.

    Not in our library10.1016/j.tem.2008.10.004

11. 11.

    Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63:7436-7442.

    Not in our library

12. 12.

    Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010;35:208-219.

    Not in our library10.1016/j.tibs.2009.12.003

13. 13.

    Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614-620.

    Not in our library10.1038/nature08356

14. 14.

    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote B, Rustin GJS, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol. 2011;29.

    Not in our library

15. 15.

    Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287-294.

    Not in our library10.1038/nature10760

16. 16.

    Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst). 2008;7:2010-2019.

    Not in our library10.1016/j.dnarep.2008.08.014

17. 17.

    Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.

    Not in our library10.1038/nature10166

18. 18.

    Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.

    Not in our library10.1038/nrc1457

19. 19.

    Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008;27:1368-1377.

    Not in our library10.1038/emboj.2008.61

20. 20.

    Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, Bernier C, Branchaud S, Chan H, Dairi K, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol. 2009;29:5872-5888.

    Not in our library10.1128/mcb.00112-09

21. 21.

    Weidele K, Kunzmann A, Schmitz M, Beneke S, Burkle A. Ex vivo supplementation with nicotinic acid enhances cellular poly(ADP-ribosyl)ation and improves cell viability in human peripheral blood mononuclear cells. Biochem Pharmacol. 2010;80:1103-1112.

    Not in our library10.1016/j.bcp.2010.06.010

22. 22.

    Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, Schirle M, Shi X, Hild M, Bauer A, et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol. 2011;13:623-629.

    Not in our library10.1038/ncb2222

Cited by papers we hold 3

• NAD⁺ Metabolism and Regulation: Lessons From Yeast · 2020
  Not checked
• Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy · 2020
  No notice
• NAD Metabolism in Cancer Therapeutics · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.